Search by property

This page provides a simple browsing interface for finding entities described by a property and a named value. Other available search interfaces include the page property search, and the ask query builder.

List of results

• Document:USA FDA Guidance for Industry - Computerized Systems Used in Clinical Investigations May-2007  + (USA FDA Guidance for Industry - Computerized Systems Used in Clinical Investigations May-2007)
• Document:USA FDA Guidance for Industry - Computerized Systems Used in Clinical Trials 13-Apr-2015  + (USA FDA Guidance for Industry - Computerized Systems Used in Clinical Trials 13-Apr-2015)
• Document:USA FDA Guidance for Industry - Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency Mar-2020  + (USA FDA Guidance for Industry - Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency Mar-2020)
• Document:USA FDA Guidance for Industry - Electronic Source Data in Clinical Investigations Sep-2013  + (USA FDA Guidance for Industry - Electronic Source Data in Clinical Investigations Sep-2013)
• Document:USA FDA Guidance for Industry - Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring Aug-2013  + (USA FDA Guidance for Industry - Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring Aug-2013)
• Document:USA FDA INFORMATION SHEET - Recruiting Study Subjects, Guidance for Institutional Review Boards and Clinical Investigators Jan-1998  + (USA FDA INFORMATION SHEET - Recruiting Study Subjects, Guidance for Institutional Review Boards and Clinical Investigators Jan-1998)
• Document:USA FDA Information - Observations and citations 20-Mar-2024  + (USA FDA Information - Observations and citations 20-Mar-2024)
• Document:USA Informed Consent - FDA Guidance for IRBs, Clinical Investigators, and Sponsors Aug-2023  + (USA Informed Consent - FDA Guidance for IRBs, Clinical Investigators, and Sponsors Aug-2023)
• Document:USA NCI GUIDELINES FOR INVESTIGATORS: ADVERSE EVENT REPORTING REQUIREMENTS FOR DCTD (CTEP AND CIP) INDs AND IDEs 30-Aug-2024  + (USA NCI GUIDELINES FOR INVESTIGATORS: ADVERSE EVENT REPORTING REQUIREMENTS FOR DCTD (CTEP AND CIP) INDs AND IDEs 30-Aug-2024)
• Document:USA NIH - SCORE Manual N.A.  + (USA NIH - SCORE Manual N.A.)
• Document:USA NIH - SCORE Manual: Appendix Source Documents Requirements Rev 01 16-Aug-2025  + (USA NIH - SCORE Manual: Appendix Source Documents Requirements Rev 01 16-Aug-2025)
• Document:USA NIH - Glossary 27-May-2025  + (USA NIH - Glossary 27-May-2025)

• Document:USA Recognized Consensus Standards N.A.  + (USA Recognized Consensus Standards N.A.)

• Document:USA Recognized Consensus Standards - ISO 14155 21-Dec-2020  + (USA Recognized Consensus Standards - ISO 14155 21-Dec-2020)
• Document:USA U.S. Code Title 21 30-Sep-2023  + (USA U.S. Code Title 21 30-Sep-2023)
• Document:USA WARNING LETTER - Purolea Cosmetics Lab MARCS-CMS 722591 46114  + (USA WARNING LETTER - Purolea Cosmetics Lab MARCS-CMS 722591 46114)
• Document:WHO WHO - EXPERT COMMITTEE ON SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS Forty-fifth report  + (WHO WHO - EXPERT COMMITTEE ON SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS Forty-fifth report)
• Document:WHO WHO - Guidance for best practices for clinical trials 2024  + (WHO WHO - Guidance for best practices for clinical trials 2024)
• Document:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995  + (WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995)
• Document:WHO WHO - HANDBOOK FOR GOOD CLINICAL RESEARCH PRACTICE (GCP) 2005  + (WHO WHO - HANDBOOK FOR GOOD CLINICAL RESEARCH PRACTICE (GCP) 2005)
• Document:WHO WHO - ICD 11  + (WHO WHO - ICD 11)
• Document:WHO WHO Good Practices for Clinical Trial Design and Implementation 04-May-2026  + (WHO WHO Good Practices for Clinical Trial Design and Implementation 04-May-2026)
• Document:WHO World Health Organization -  + (WHO World Health Organization -)
• Document:WMA Declaration of Helsinki 2024  + (WMA Declaration of Helsinki 2024)